Algert Global LLC bought a new position in shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 77,037 shares of the company’s stock, valued at approximately $1,394,000. Algert Global LLC owned about 0.24% of Ra Pharmaceuticals at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. UBS Group AG acquired a new position in shares of Ra Pharmaceuticals in the 1st quarter worth approximately $259,000. Alps Advisors Inc. lifted its holdings in shares of Ra Pharmaceuticals by 12.6% in the 2nd quarter. Alps Advisors Inc. now owns 46,853 shares of the company’s stock worth $466,000 after acquiring an additional 5,241 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Ra Pharmaceuticals by 33.5% in the 2nd quarter. BlackRock Inc. now owns 1,537,331 shares of the company’s stock worth $15,297,000 after acquiring an additional 385,587 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Ra Pharmaceuticals by 27.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 214,579 shares of the company’s stock worth $2,135,000 after acquiring an additional 46,126 shares during the last quarter. Finally, FMR LLC acquired a new position in shares of Ra Pharmaceuticals in the 2nd quarter worth approximately $807,000. Hedge funds and other institutional investors own 74.74% of the company’s stock.
Several equities analysts have recently commented on RARX shares. BidaskClub upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. ValuEngine upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 22nd. Raymond James upgraded shares of Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price objective on the stock in a report on Wednesday, October 10th. Credit Suisse Group set a $25.00 price objective on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, October 19th. Finally, Zacks Investment Research lowered shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $21.50.
Shares of RARX stock opened at $16.46 on Friday. Ra Pharmaceuticals Inc has a one year low of $4.78 and a one year high of $19.43. The company has a market capitalization of $524.52 million, a PE ratio of -6.83 and a beta of 2.11.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). Research analysts anticipate that Ra Pharmaceuticals Inc will post -2.11 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Algert Global LLC Takes Position in Ra Pharmaceuticals Inc (RARX)” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/12/08/algert-global-llc-takes-position-in-ra-pharmaceuticals-inc-rarx.html.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmaceuticals Inc (NASDAQ:RARX).
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.